Iranian Journal of Microbiology,
Год журнала:
2023,
Номер
unknown
Опубликована: Апрель 16, 2023
Background
and
Objectives:
Since
the
coronavirus
disease
2019
(COVID-19)
pandemic
began,
several
vaccines
have
been
manufactured
to
subside
it.
This
study
aimed
determine
prevalence
of
side
effects
after
injecting
common
COVID-19
available
in
Iran.
Materials
Methods:
cross-sectional
was
accomplished
on
Shahid
Beheshti
University
Medical
Sciences
(Tehran,
Iran)
employees
during
January
September
2022.
Eligible
participants
were
selected
based
simple
ran-
dom
method
interviewed
about
vaccine.
Results:
The
mean
age
656
38.03
±
9.53
years,
453
(69.1%)
female.
post-vac-
cination
higher
receiving
first
dose
(53.2%)
than
second
(35.9%)
third
(49.4%)
doses.
Across
all
three
vaccine
doses,
overall
proportion
following
AstraZeneca
others.
most
effect
myalgia
(41.9%),
followed
by
fever
(36.6%),
chills
(31.6%),
local
reactions
(27.0%),
headache
(25.5%),
sweating
(21.6%).
People
experienced
mainly
(23.3%)
(20.3%)
Additionally,
had
(37.2%),
(30.8%),
(29.2%),
(26.0%),
(24.4%)
Conclusion:
a
post-vaccination
adverse
Sputnik
V,
Pastocovac,
Sin-
opharm.
flu-like
syndrome
at
injection
site.
Furthermore,
people
rarely
life-threatening
effects.
Thus,
Iran
are
safe.
Vaccination
is
one
of
the
effective
ways
to
fight
against
COVID-19
disease.
Various
vaccines
have
been
designed
during
coronavirus
pandemic.
Each
used
has
beneficial
effects
as
well
side
effects.
Healthcare
workers
were
among
first
vaccinated
persons
in
different
countries.
The
current
study
aims
compare
AstraZeneca,
Sinopharm,
Bharat,
and
Sputnik
V
on
healthcare
Iran.This
descriptive
was
conducted
from
July
2021
January
2022
1639
who
received
vaccines.
Data
collected
using
a
checklist
that
contained
questions
related
systemic,
local,
severe
vaccine.
data
analyzed
Kruskal-Wallis,
Chi-square,
trend
chi-square.
P
<
.05
regarded
significant
statistical
difference.The
most
commonly
injected
Sinopharm
(41.80%),
(36.65%),
AstraZeneca
(17.75%),
Bharat
(3.80%),
respectively.
At
least
37.5%
participants
reported
complication.
common
after
72
hours
second
doses
follows:
injection
site
pain,
fatigue,
fever,
myalgia,
headache,
chill.
Overall
complication
rates
(91.4%),
(65.9%),
(56.8%),
(98.4%).
showed
highest
overall
effects,
while
had
lowest
Also,
our
results
indicated
individuals
with
previous
history
positive
infection
higher
rate
complications.The
majority
did
not
show
life-threatening
1
4
studied
Since
it
accepted
tolerable
by
participants,
can
be
widely
safely
SARS-CoV-2.
International Journal of Applied Pharmaceutics,
Год журнала:
2022,
Номер
unknown, С. 22 - 30
Опубликована: Апрель 1, 2022
Objective:
To
evaluate
the
comparison
between
Sinovac
vaccine
and
Pfizer
for
children
teenagers
under
18
y
in
Indonesia
other
factors
that
influence
it.
Methods:
The
type
of
this
research
is
observational
with
a
cross-sectional
design
using
convenience
sampling
all
teenager
who
has
received
full
dose
vaccine.
Results:
It
was
found
efficacy
vaccines
99.5%
99.75%,
respectively.
Other
side
effects
are
gender,
age,
BMI,
p-value
each
variable<0.05.
Conclusion:
There
correlation
vaccine,
BMI
vaccination.
Frontiers in Cellular and Infection Microbiology,
Год журнала:
2022,
Номер
12
Опубликована: Ноя. 3, 2022
We
evaluated
the
immunogenicity
and
protective
ability
of
a
chimpanzee
replication-deficient
adenovirus
vectored
COVID-19
vaccine
(BV-AdCoV-1)
expressing
stabilized
pre-fusion
SARS-CoV-2
spike
glycoprotein
in
golden
Syrian
hamsters.
Intranasal
administration
BV-AdCoV-1
elicited
strong
humoral
cellular
immunity
animals.
Furthermore,
vaccination
prevented
weight
loss,
reduced
infectious
virus
titers
lungs
as
well
lung
pathology
provided
protection
against
live
challenge.
In
addition,
there
was
no
vaccine-induced
enhanced
disease
nor
immunopathological
exacerbation
BV-AdCoV-1-vaccinated
induced
cross-neutralizing
antibody
responses
ancestral
strain
B.1.617.2,
Omicron(BA.1),
Omicron(BA.2.75)
Omicron(BA.4/5)
variants
concern.
These
results
demonstrate
that
is
potentially
promising
candidate
to
prevent
infection,
curtail
pandemic
spread
humans.
Life,
Год журнала:
2022,
Номер
12(12), С. 2046 - 2046
Опубликована: Дек. 7, 2022
The
concern
about
post-COVID-19
vaccine
complications
still
remains.
In
addition,
the
evidence
on
Sinopharm,
Sputnik
V,
Covaxin,
and,
in
particular,
COVIran
Barekat,
as
well
comparisons
between
them
by
dosage
after
post-vaccination,
is
scarce.
This
study
aimed
to
investigate
and
compare
prevalence
of
self-reported
post-vaccination
signs
symptoms
following
first
second
doses
different
types
COVID-19
vaccines.
Research
design
methods:
prospective
cohort
was
conducted
more
than
1500
health
professionals
who
had
received
at
least
one
dose
any
type
Oxford
AstraZeneca,
Barekat
vaccines
Iran.
survey
questionnaire
sent
participants
online,
28
days
receiving
each
vaccine.
Results:
About
73%
reported
sign
or
symptom,
developing
mostly
within
12
h
(69.9%)
lasting
up
(59.0%).
Pain
tenderness
injection
site,
fever,
muscle
pain
were
most
common
all
vaccines,
which
significantly
higher
AstraZeneca
(p
<
0.001)
for
both
doses.
incidence
rate
0.05).
Conclusion:
showed
highest
rate,
onset,
time
doses;
however,
they
not
life-threatening.
onset
Iranian Journal of Microbiology,
Год журнала:
2023,
Номер
unknown
Опубликована: Апрель 16, 2023
Background
and
Objectives:
Since
the
coronavirus
disease
2019
(COVID-19)
pandemic
began,
several
vaccines
have
been
manufactured
to
subside
it.
This
study
aimed
determine
prevalence
of
side
effects
after
injecting
common
COVID-19
available
in
Iran.
Materials
Methods:
cross-sectional
was
accomplished
on
Shahid
Beheshti
University
Medical
Sciences
(Tehran,
Iran)
employees
during
January
September
2022.
Eligible
participants
were
selected
based
simple
ran-
dom
method
interviewed
about
vaccine.
Results:
The
mean
age
656
38.03
±
9.53
years,
453
(69.1%)
female.
post-vac-
cination
higher
receiving
first
dose
(53.2%)
than
second
(35.9%)
third
(49.4%)
doses.
Across
all
three
vaccine
doses,
overall
proportion
following
AstraZeneca
others.
most
effect
myalgia
(41.9%),
followed
by
fever
(36.6%),
chills
(31.6%),
local
reactions
(27.0%),
headache
(25.5%),
sweating
(21.6%).
People
experienced
mainly
(23.3%)
(20.3%)
Additionally,
had
(37.2%),
(30.8%),
(29.2%),
(26.0%),
(24.4%)
Conclusion:
a
post-vaccination
adverse
Sputnik
V,
Pastocovac,
Sin-
opharm.
flu-like
syndrome
at
injection
site.
Furthermore,
people
rarely
life-threatening
effects.
Thus,
Iran
are
safe.
